AVROBIO announced that the first patient has been dosed in the company’s GuardOne clinical trial, a Phase 1/2 investigational study evaluating AVR-RD-02 for Gaucher disease type 1.
Sunovion Pharmaceuticals said that a phase 2 study evaluating SEP-4199 as the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression) failed to meet its primary endpoint.
Sinovac Biotech ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines.
Regeneron Pharmaceuticals has announced the commencement of Phase 3 trial with its investigational double-antibody cocktail REGN-COV2 to treat and prevent Covid-19 disease.
Idorsia announced positive top-line results of the second pivotal Phase 3 study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant, in 924 adult and elderly patients (39.3% ≥ 65 years) with insomnia.
EUSA Pharma said that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).
Daiichi Sankyo Company announced the first patient with triple negative breast cancer (TNBC) has been dosed in the ongoing phase 1 study assessing DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC).
Pfizer and BioNTech announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine programme , Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic.
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been previously treated with one novel hormonal therapy.
NuvOx Pharma, a Tucson-based biotechnology company developing NanO2 emulsion for oxygen delivery, has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.